Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dexlar: Exenatide-LAR and Dapagliflozin in T2DM
NCT02811484Phase 4Withdrawn
- Sponsor
- Weill Cornell Medicine
- Start
- Jun 2016
- Primary completion
- Jun 2018
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of exenatide, dapagliflozin in type 2 diabetes mellitus (T2DM), sponsored by Weill Cornell Medicine. Planned start Jun 2016; status: withdrawn.
02
Drugs
exenatidedapagliflozin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT02811484.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02811484.